Two Activist Plays And Two Biotech Moves You Should Check Out

Biotech wiz Peter Kolchinsky has also revealed two recent moves. According to a filing with the Securities and Exchange Commission, he has boosted his investment in Alcobra Ltd (NASDAQ:ADHD) to 3.03 million shares from the previous holding of 1.66 million shares. As a result, RA Capital Management has control over 11.1% of the company’s outstanding shares. The stock is currently trading at $6.19, up by 64% so far this year.

Hedge funds in our database have an overwhelming presence among the shareholders of Alcobra Ltd (NASDAQ:ADHD), together controlling 58% of its shares outstanding at the end of the third quarter. The number of funds invested in the company increased to 14 on September 30, from 12 at the end of June. On the other hand, Kevin Kotler, another biotech expert, decided to reduce his exposure to Alcobra Ltd (NASDAQ:ADHD) during the third quarter, cutting his stake to 1.55 million shares. Jeffrey Jay and David Kroin, the managers of Great Point Partners, think Alcobra still has room to grow and have upped their stake in the company to a little over 1.2 million shares valued at $7.28 million.

In a recent Form 4 filing with the SEC, RA Capital Management has also disclosed an increase to its holding of Wave Life Sciences Ltd (NASDAQ:WVE), to 7.08 million shares. Roughly 1.87 million shares were acquired on the open market for an average price of $16.00 apiece, while a further 1.17 million shares were converted from Series B preferred stock to ordinary stock, on a one-to-one basis. Wave Life Sciences went public on November 11 in an IPO priced at $16.00 per share, raising a little over $100 million. RA Capital is the first among the hedge funds we follow that has reported a stake in Wave Life Sciences Ltd (NASDAQ:WVE).

Disclosure: None